Response to 2-Chlorodeoxyadenosine in Patients with B-Cell Chronic Lymphocytic Leukemia Resistant to Fludarabine

8 October 1992

journal article
clinical trial
Published by Massachusetts Medical Society in New England Journal of Medicine

Vol. 327 (15) , 1056-1061
https://doi.org/10.1056/nejm199210083271504

Abstract

Patients with untreated B-cell chronic lymphocytic leukemia have a high rate of complete remission when given the halogenated nucleoside analogue fludarabine. However, patients in whom the disease has proved refractory to primary treatment have a reduced life expectancy and a dismal outcome.

Keywords

This publication has 13 references indexed in Scilit:

On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration.
Journal of Clinical Oncology, 1992
2-Chlorodeoxyadenosine (2-CdA): A Potent Chemotherapeutic and Immunosuppressive Nucleoside
Leukemia & Lymphoma, 1991
Current Status of U.S. Clinical Trials in Chronic Lymphocytic Leukemia
Leukemia & Lymphoma, 1991
Prognostic Subgroups in B-Cell Chronic Lymphocytic Leukemia Defined by Specific Chromosomal Abnormalities
New England Journal of Medicine, 1990
Lasting Remissions in Hairy-Cell Leukemia Induced by a Single Infusion of 2-Chlorodeoxyadenosine
New England Journal of Medicine, 1990
Lethal Disseminated Adenovirus Type 1 Infection in a Patient with Chronic Lymphocytic Leukemia
Scandinavian Journal of Infectious Diseases, 1990
Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the national cancer institute‐sponsored working group
American Journal of Hematology, 1988
Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes.
Journal of Clinical Investigation, 1985
Antileukemic and immunosuppressive activity of 2-chloro-2'-deoxyadenosine.
Proceedings of the National Academy of Sciences, 1984
A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis
Cancer, 1981